Literature DB >> 25546743

Dose and outcomes in primary immunodeficiency disorders.

V R Bonagura1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25546743      PMCID： PMC4285472          DOI： 10.1111/cei.12492

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  13 in total

1.  Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection.

Authors:  Vincent R Bonagura; Robert Marchlewski; Amanda Cox; David W Rosenthal
Journal:  J Allergy Clin Immunol       Date:  2008-07       Impact factor: 10.793

2.  Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years.

Authors:  Mary Lucas; Martin Lee; Jenny Lortan; Eduardo Lopez-Granados; Siraj Misbah; Helen Chapel
Journal:  J Allergy Clin Immunol       Date:  2010-05-14       Impact factor: 10.793

3.  Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home.

Authors:  Uwe Nicolay; Peter Kiessling; Melvin Berger; Sudhir Gupta; Leman Yel; Chaim M Roifman; Ann Gardulf; Florian Eichmann; Stefan Haag; Cordula Massion; Hans D Ochs
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

4.  Longitudinal decline in lung function in patients with primary immunoglobulin deficiencies.

Authors:  Yan Chen; Rob G Stirling; Eldho Paul; Fiona Hore-Lacy; Bruce R Thompson; Jo A Douglass
Journal:  J Allergy Clin Immunol       Date:  2011-05-04       Impact factor: 10.793

Review 5.  Subcutaneous immunoglobulin: opportunities and outlook.

Authors:  S Misbah; M H Sturzenegger; M Borte; R S Shapiro; R L Wasserman; M Berger; H D Ochs
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

6.  Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies.

Authors:  Jordan S Orange; William J Grossman; Roberta J Navickis; Mahlon M Wilkes
Journal:  Clin Immunol       Date:  2010-08-01       Impact factor: 3.969

7.  Percentile ranges for serum IgG subclass concentrations in healthy Chinese children.

Authors:  Y L Lau; B M Jones; K W Ng; C Y Yeung
Journal:  Clin Exp Immunol       Date:  1993-02       Impact factor: 4.330

8.  Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study.

Authors:  Isabella Quinti; Annarosa Soresina; Andrea Guerra; Roberto Rondelli; Giuseppe Spadaro; Carlo Agostini; Cinzia Milito; Amelia Chiara Trombetta; Marcella Visentini; Helene Martini; Alessandro Plebani; Massimo Fiorilli
Journal:  J Clin Immunol       Date:  2011-03-02       Impact factor: 8.317

9.  Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency.

Authors:  Javier de Gracia; Montserrat Vendrell; Antonio Alvarez; Esther Pallisa; Maria-José Rodrigo; David de la Rosa; Fernando Mata; Jordi Andreu; Ferran Morell
Journal:  Int Immunopharmacol       Date:  2004-06       Impact factor: 4.932

Review 10.  Genetic causes of bronchiectasis: primary immune deficiencies and the lung.

Authors:  Luigi D Notarangelo; Alessandro Plebani; Evelina Mazzolari; Annarosa Soresina; Maria Pia Bondioni
Journal:  Respiration       Date:  2007       Impact factor: 3.580
View more
  4 in total

1.  Dealing With Immunoglobulin Shortages: A Rationalization Plan From Evidence-Based and Data Collection.

Authors:  Gerard Solís-Díez; Marta Turu-Pedrola; Marta Roig-Izquierdo; Corinne Zara; Antoni Vallano; Caridad Pontes
Journal:  Front Public Health       Date:  2022-05-19

2.  Initial intravenous immunoglobulin doses should be based on adjusted body weight in obese patients with primary immunodeficiency disorders.

Authors:  Rohan Ameratunga
Journal:  Allergy Asthma Clin Immunol       Date:  2017-12-06       Impact factor: 3.406

3.  II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies.

Authors:  Ekaterini Simões Goudouris; Almerinda Maria do Rego Silva; Aluce Loureiro Ouricuri; Anete Sevciovic Grumach; Antonio Condino-Neto; Beatriz Tavares Costa-Carvalho; Carolina Cardoso Prando; Cristina Maria Kokron; Dewton de Moraes Vasconcelos; Fabíola Scancetti Tavares; Gesmar Rodrigues Silva Segundo; Irma Cecília Barreto; Mayra de Barros Dorna; Myrthes Anna Barros; Wilma Carvalho Neves Forte
Journal:  Einstein (Sao Paulo)       Date:  2017

4.  Health-Related Quality of Life in Adult Patients with Common Variable Immunodeficiency Disorders and Impact of Treatment.

Authors:  Nicholas L Rider; Carleigh Kutac; Joud Hajjar; Chris Scalchunes; Filiz O Seeborg; Marcia Boyle; Jordan S Orange
Journal:  J Clin Immunol       Date:  2017-05-23       Impact factor: 8.317
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.